BioCentury | May 25, 2018
Clinical News

Sesen reports Phase III data for bladder cancer candidate Vicinium

...Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of...
...surface of tumor cells to deliver the Pseudomonas exotoxin A directly to cancer cells. Mary Romeo Vicinium (VB4-845) Eleven Biotherapeutics Inc. Epithelial...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

.../ Merck & Co. Inc. (NYSE:MRK) Lenvima lenvatinib mesylate Hepatocellular carcinoma (HCC) PDUFA date 5/24/18 Eleven Biotherapeutics Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:VYGR) 11/7/17 $62.1 $385.5 $533.3 38% Assembly Biosciences Inc. (NASDAQ:ASMB) 11/2/17 $60.2 $534.3 $887.2 66% Eleven Biotherapeutics Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Co. Ltd. (Tokyo:4523) / Purdue Pharma L.P. Lemborexant Insomnia Ph III Study 304 data 1Q18 Eleven Biotherapeutics Inc....
BioCentury | Oct 16, 2017
Company News

Management tracks: Apeiron, Tetraphase

...non-executive chair of its board. She is CEO at Dimension Therapeutics Inc. (NASDAQ:DMTX). Oncology play Eleven Biotherapeutics Inc....
BioCentury | Jul 7, 2017
Clinical News

DSMB recommends continuation of Phase III Vicinium trial in NMIBC

...26, 2016 ). Vicinium is a tumor targeting antibody fragment conjugated with Pseudomonas exotoxin A. Eleven Biotherapeutics Inc....
...OS) Status: Phase III ongoing Milestone: Complete Phase III enrollment (2H17); Phase III data (2Q18) Alex Himes VB4-845 Vicinium Eleven Biotherapeutics Inc. Epithelial...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Cancer

...malignant ascites and have the antibody in Phase II testing for gastric and ovarian cancers. Eleven Biotherapeutics Inc....
...CONTACT: Haiming Wei, University of Science and Technology of China, Anhui, China email: ustcwhm@ustc.edu.cn Karen Tkach Amgen Inc. Eleven Biotherapeutics Inc. Fresenius...
BioCentury | Oct 31, 2016
Top Story

Third Rock closes fourth fund at $616M

...firm named Abbie Celniker partner. She was president and CEO of Third Rock portfolio company Eleven Biotherapeutics Inc....
BioCentury | Sep 26, 2016
Company News

Viventia, Eleven Biotherapeutics deal

...The companies did not respond in time for publication. Viventia Bio Inc. , Mississauga, Ontario Eleven Biotherapeutics Inc....
BioCentury | Sep 21, 2016
Company News

Viventia finds public path via Eleven

...Ophthalmic therapeutics company Eleven Biotherapeutics Inc. (NASDAQ:EBIO) acquired cancer company Viventia Bio Inc. (Mississauga, Ontario), which had been...
Items per page:
1 - 10 of 73
BioCentury | May 25, 2018
Clinical News

Sesen reports Phase III data for bladder cancer candidate Vicinium

...Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of...
...surface of tumor cells to deliver the Pseudomonas exotoxin A directly to cancer cells. Mary Romeo Vicinium (VB4-845) Eleven Biotherapeutics Inc. Epithelial...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

.../ Merck & Co. Inc. (NYSE:MRK) Lenvima lenvatinib mesylate Hepatocellular carcinoma (HCC) PDUFA date 5/24/18 Eleven Biotherapeutics Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:VYGR) 11/7/17 $62.1 $385.5 $533.3 38% Assembly Biosciences Inc. (NASDAQ:ASMB) 11/2/17 $60.2 $534.3 $887.2 66% Eleven Biotherapeutics Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Co. Ltd. (Tokyo:4523) / Purdue Pharma L.P. Lemborexant Insomnia Ph III Study 304 data 1Q18 Eleven Biotherapeutics Inc....
BioCentury | Oct 16, 2017
Company News

Management tracks: Apeiron, Tetraphase

...non-executive chair of its board. She is CEO at Dimension Therapeutics Inc. (NASDAQ:DMTX). Oncology play Eleven Biotherapeutics Inc....
BioCentury | Jul 7, 2017
Clinical News

DSMB recommends continuation of Phase III Vicinium trial in NMIBC

...26, 2016 ). Vicinium is a tumor targeting antibody fragment conjugated with Pseudomonas exotoxin A. Eleven Biotherapeutics Inc....
...OS) Status: Phase III ongoing Milestone: Complete Phase III enrollment (2H17); Phase III data (2Q18) Alex Himes VB4-845 Vicinium Eleven Biotherapeutics Inc. Epithelial...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Cancer

...malignant ascites and have the antibody in Phase II testing for gastric and ovarian cancers. Eleven Biotherapeutics Inc....
...CONTACT: Haiming Wei, University of Science and Technology of China, Anhui, China email: ustcwhm@ustc.edu.cn Karen Tkach Amgen Inc. Eleven Biotherapeutics Inc. Fresenius...
BioCentury | Oct 31, 2016
Top Story

Third Rock closes fourth fund at $616M

...firm named Abbie Celniker partner. She was president and CEO of Third Rock portfolio company Eleven Biotherapeutics Inc....
BioCentury | Sep 26, 2016
Company News

Viventia, Eleven Biotherapeutics deal

...The companies did not respond in time for publication. Viventia Bio Inc. , Mississauga, Ontario Eleven Biotherapeutics Inc....
BioCentury | Sep 21, 2016
Company News

Viventia finds public path via Eleven

...Ophthalmic therapeutics company Eleven Biotherapeutics Inc. (NASDAQ:EBIO) acquired cancer company Viventia Bio Inc. (Mississauga, Ontario), which had been...
Items per page:
1 - 10 of 73